Kristin B Highland

Summary

Affiliation: Medical University of South Carolina
Country: USA

Publications

  1. ncbi request reprint New developments in scleroderma interstitial lung disease
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    Curr Opin Rheumatol 17:737-45. 2005
  2. ncbi request reprint The spectrum of scleroderma lung disease
    Kristin B Highland
    Division of Pulmonary Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Semin Respir Crit Care Med 28:418-29. 2007
  3. doi request reprint Pulmonary arterial hypertension
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Med Sci 335:40-5. 2008
  4. ncbi request reprint Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a long-term benefit?
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, South Carolina, USA
    Curr Opin Pulm Med 10:113-9. 2004
  5. ncbi request reprint Treatment of pulmonary arterial hypertension: a preliminary decision analysis
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy, and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 812 CSB, Charleston, SC 29425, USA
    Chest 124:2087-92. 2003
  6. ncbi request reprint Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Box 250623, Charleston, South Carolina 29425, USA
    Ann Intern Med 138:969-73. 2003
  7. ncbi request reprint Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways
    Galina S Bogatkevich
    Medical University of South Carolina, Charleston, SC 29425, USA
    Arthritis Rheum 56:3468-77. 2007
  8. ncbi request reprint Interstitial lung disease in the patient who has connective tissue disease
    Charlie Strange
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Charleston, SC 29425, USA
    Clin Chest Med 25:549-59, vii. 2004
  9. ncbi request reprint A "story" of a woman with cystic fibrosis
    Kristin B Highland
    Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    Chest 121:1704-7. 2002
  10. doi request reprint Chronic dyspnea and severe obstruction after pneumonectomy: postpneumonectomy syndrome
    Meena Kalluri
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Med Sci 336:530-1. 2008

Detail Information

Publications19

  1. ncbi request reprint New developments in scleroderma interstitial lung disease
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    Curr Opin Rheumatol 17:737-45. 2005
    ....
  2. ncbi request reprint The spectrum of scleroderma lung disease
    Kristin B Highland
    Division of Pulmonary Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Semin Respir Crit Care Med 28:418-29. 2007
    ..For each manifestation we outline the current knowledge of etiology, risk factors, diagnosis, treatment, and prognosis. We also discuss the current state of lung transplantation in this population...
  3. doi request reprint Pulmonary arterial hypertension
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Med Sci 335:40-5. 2008
    ..Multiple effective therapies now exist for pulmonary arterial hypertension, and thus early diagnosis and referral will translate into meaningful survival and better lives for our patients...
  4. ncbi request reprint Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a long-term benefit?
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, South Carolina, USA
    Curr Opin Pulm Med 10:113-9. 2004
    ..Experts disagree about the benefits and harms of ICS for patients with COPD, yet a majority of patients with COPD are being treated with inhaled corticosteroids. This is a review of the most recent literature on this subject...
  5. ncbi request reprint Treatment of pulmonary arterial hypertension: a preliminary decision analysis
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy, and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 812 CSB, Charleston, SC 29425, USA
    Chest 124:2087-92. 2003
    ..Clinicians must chose between very different therapies without the availability of comparison studies. We constructed a "virtual" clinical trial to help inform these treatment choices...
  6. ncbi request reprint Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis
    Kristin B Highland
    Division of Pulmonary, Critical Care, Allergy and Clinical Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Box 250623, Charleston, South Carolina 29425, USA
    Ann Intern Med 138:969-73. 2003
    ..There is no consensus on the effectiveness of inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease (COPD)...
  7. ncbi request reprint Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways
    Galina S Bogatkevich
    Medical University of South Carolina, Charleston, SC 29425, USA
    Arthritis Rheum 56:3468-77. 2007
    ..To study the mechanisms by which hepatocyte growth factor (HGF) down-regulates collagen and connective tissue growth factor (CTGF) in scleroderma (systemic sclerosis [SSc]) lung fibroblasts...
  8. ncbi request reprint Interstitial lung disease in the patient who has connective tissue disease
    Charlie Strange
    Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, 812 CSB, Charleston, SC 29425, USA
    Clin Chest Med 25:549-59, vii. 2004
    ..Additionally, the challenge of finding the patient who has occult connective tissue disease in an interstitial lung disease clinic is discussed...
  9. ncbi request reprint A "story" of a woman with cystic fibrosis
    Kristin B Highland
    Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    Chest 121:1704-7. 2002
    ..Such knowledge is likely to result in less harm to the patient through unnecessary testing and treatment...
  10. doi request reprint Chronic dyspnea and severe obstruction after pneumonectomy: postpneumonectomy syndrome
    Meena Kalluri
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Med Sci 336:530-1. 2008
    ..Postpneumonectomy syndrome is treated by surgical repositioning of the mediastinum. Knowledge of the clinical and radiological features will enable prompt diagnosis and appropriate treatment...
  11. ncbi request reprint Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis
    Galina S Bogatkevich
    Medical University of South Carolina, Charleston 29425, USA
    Arthritis Rheum 56:2432-42. 2007
    ..To compare the composition of cytokines in African American and Caucasian patients with systemic sclerosis (SSc; scleroderma) and in healthy individuals, particularly the expression and function of hepatocyte growth factor (HGF)...
  12. ncbi request reprint Pulmonary hypertension in interstitial lung disease
    Charlie Strange
    Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Curr Opin Pulm Med 11:452-5. 2005
    ..Antifibrotic therapies for interstitial lung disease remain unproved; therefore, some interest has been focused on treating the pulmonary vascular impairment these diseases...
  13. ncbi request reprint Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study
    Kristin B Highland
    Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912 CSB, Charleston, SC 29425, USA
    Curr Rheumatol Rep 7:135-41. 2005
    ..A randomized controlled trial, the Scleroderma Lung Study (SLS), will be completed in 2005; the outcome of the SLS should define the efficacy of daily oral cyclophosphamide for SSc-ILD patients with alveolitis defined by BALF and HRCT...
  14. ncbi request reprint Pleural effusion in interstitial lung disease
    Kristin B Highland
    Division of Pulmonary Critical Care Medicine and Allergy, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Curr Opin Pulm Med 10:390-6. 2004
    ..This review reports recent information on the occurrence of pleural effusions in association with disorders that produce interstitial parenchymal lung disease...
  15. pmc The PPARĪ³ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
    Galina S Bogatkevich
    Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas Street, Suite 912, Charleston, SC 29425 6370, USA
    Pulm Med 2012:545172. 2012
    ..Differential therapeutic effects might be anticipated especially relative to racial differences and the functional expression of the c-Met receptor...
  16. ncbi request reprint Chronic obstructive pulmonary disease in geriatric critical care
    John E Heffner
    Pulmonary Divison, 812 CSB, Medical University of South Carolina, 96 Jonathan Lucas Street, P O Box 250623, Charleston, SC 29425, USA
    Crit Care Clin 19:713-27. 2003
    ..Most patients survive hospitalization in the ICU for an episode of respiratory failure. The severity of the underlying lung disease, however, underlies the poor outcomes of patients in terms of postdischarge survival and quality of life...
  17. doi request reprint Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature
    Meena Kalluri
    Division of Pulmonary and Critical Care Medicine, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston, SC, USA
    Chest 135:1550-6. 2009
    ..The purpose of this study was to examine the clinical profile of anti-PL-12, an antisynthetase autoantibody directed against alanyl-transfer RNA synthetase...
  18. ncbi request reprint Critical care challenges in the adult ECMO patient
    Sarah E Gay
    Duke University School of Nursing, Durham, North Carolina, USA
    Dimens Crit Care Nurs 24:157-62; quiz 163-4. 2005
    ..Although ECMO is not new to the intensive care unit setting, it is usually considered a last resort measure in the adult population. ECMO may save a life and present an awarding challenge to the intensive care unit nurse...
  19. doi request reprint Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival
    Raymond L Benza
    University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
    Chest 134:775-82. 2008
    ..Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study...